Euroopan unioni - suomi - EMA (European Medicines Agency)

bavarian nordic a/s - muunnettu vaccinia ankara - baijerin pohjoismainen (mva-bn) -virus - smallpox vaccine; monkeypox virus - muut virusrokotteet, - active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4. 4 ja 5. käyttö tämä rokote tulee virallisten suositusten mukaisesti.

Euroopan unioni - suomi - EMA (European Medicines Agency)

siga technologies netherlands b.v. - tecovirimat - poxviridae infections; cowpox; monkeypox; vaccinia; smallpox - antiviraalit systeemiseen käyttöön - tecovirimat siga is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg:- smallpox- monkeypox- cowpoxtecovirimat siga is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg (see sections 4. 4 ja 5. tecovirimat siga should be used in accordance with official recommendations.

Suomi - suomi - Fimea (Suomen lääkevirasto)

zoetis animal health aps - canine distemper virus, strain cdv bio 11/a, live attenuated, canine adenovirus type 2, strain cav-2 bio 13, live attenuated, canine parvovirus type 2b, strain cpv-2b bio 12/b, live attenuated - kuiva-aine, kylmäkuivattu, ja liuotin, injektionestettä varten, suspensio - koiran penikkatautivirus - + koiran tarttuva maksatulehdusvirus - + koiran parvovirus -rokote

Euroopan unioni - suomi - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - rokotteet - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. käyttö tämä rokote tulee virallisten suositusten mukaisesti.

Euroopan unioni - suomi - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. käyttö tämä rokote tulee virallisten suositusten mukaisesti.

Suomi - suomi - Fimea (Suomen lääkevirasto)

lohmann animal health gmbh - avian encephalomyelitis virus, live (ae) - konsentraatti oraalisuspensiota varten

Suomi - suomi - Fimea (Suomen lääkevirasto)

lohmann animal health gmbh - chicken anaemia virus, live - kuiva-aine, kylmäkuivattu, juomaveteen sekoitettavaksi - sinisiipitauti -rokote

Euroopan unioni - suomi - EMA (European Medicines Agency)

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - rokotteet - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 ja 5. 1 in product information document). käyttö tämä rokote tulee virallisten suositusten mukaisesti.

Suomi - suomi - Fimea (Suomen lääkevirasto)

sandoz a/s - tacrolimus monohydrate - kapseli, kova - 2 mg - takrolimuusi

Suomi - suomi - Fimea (Suomen lääkevirasto)

sandoz a/s - tacrolimus monohydrate - kapseli, kova - 0.75 mg - takrolimuusi